Crispr Therapeutics Q3 Earnings: No Casgevy Revenue, But Plenty Of Optimism
Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...
Politico Europe2d
Victors in the race for emerging tech will determine future
Collectively, emerging technologies are creating an unstable world, where we don’t clearly understand what national security ...
Medindia4d
Synthetic Biology Market to Hit USD 31.52 Billion by 2029 with 20.6% CAGR | MarketsandMarkets™
The tool segment is segmented into oligonucleotides & synthetic DNA, enzymes, cloning technology kits, chassis organisms ... range of products for the synthetic biology industry, such as CRISPR & Gene ...
Synthetic Biology Market to Hit USD 31.52 Billion by 2029 with 20.6% CAGR | MarketsandMarkets
The global synthetic biology market is anticipated to reach USD 31.52 billion in 2029 from USD 12.33 billion in 2024, with a ...
Nature2d
CRISPR builds a big tomato that’s actually sweet
Rotten tomatoes no more: growing sweeter tomatoes is possible by editing just two of the fruit’s genes. Deleting the genes ...
Yahoo Finance1d
Genomics Market to Hit USD 66.85 Billion by 2029 with 9.4% CAGR | MarketsandMarkets™
The product segment accounted for the largest share of the genomics market in 2023. This dominance is primarily attributable ...
News Medical1d
CN Bio launches PhysioMimix Bioavailability assay kit: Human 18
CN Bio, a leading provider of Organ-on-a-chip Systems and solutions that accelerate drug discovery and development workflows, today announced the launch of its PhysioMimix® Bioavailability assay kit: ...